Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/79778
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVandyke, K.en
dc.contributor.authorChow, A.en
dc.contributor.authorWilliams, S.en
dc.contributor.authorTo, L.en
dc.contributor.authorZannettino, A.en
dc.date.issued2013en
dc.identifier.citationBritish Journal of Haematology, 2013; 161(4):499-507en
dc.identifier.issn0007-1048en
dc.identifier.issn1365-2141en
dc.identifier.urihttp://hdl.handle.net/2440/79778-
dc.description.abstractN-cadherin (cadherin 2, type 1, N-cadherin (neuronal); CDN2) is a homotypic adhesion molecule that is upregulated in breast, prostate and bladder cancer. Here we investigated the prognostic significance of upregulated N-cadherin expression in multiple myeloma (MM). Our results indicate that N-cadherin protein and gene expression is abnormally increased in trephine biopsies and CD38⁺⁺/CD138⁺ plasma cells from MM patients, when compared with those of normal donors. In addition, levels of circulating N-cadherin were elevated in a subset of patients with MM (n = 81; mean: 14·50 ng/ml, range: 0–146·78 ng/ml), relative to age-matched controls (n = 27; mean: 2·66 ng/ml, range: 0–5·96 ng/ml), although this did not reach statistical significance. Notably, patients with abnormally high levels of N-cadherin (>6 ng/ml) had decreased progression-free survival (P = 0·036; hazard ratio: 1·94) and overall survival (P = 0·002; hazard ratio: 3·15), when compared with patients with normal N-cadherin levels (≤6 ng/ml). Furthermore, multivariate analyses revealed that the combination of N-cadherin levels and International Staging System (ISS) was a more powerful prognostic indicator than using ISS alone. Collectively, our studies demonstrate that circulating N-cadherin levels are a viable prognostic marker for high-risk MM patients.en
dc.description.statementofresponsibilityKate Vandyke, Annie W.S. Chow, Sharon A. Williams, Luen B. To and Andrew C.W. Zannettinoen
dc.language.isoenen
dc.publisherBlackwell Publishing Ltden
dc.rights© 2013 John Wiley & Sons Ltden
dc.subjectmultiple myeloma; N-cadherin; prognostic marker, novel therapeutic target, ISSen
dc.titleCirculating N-cadherin levels are a negative prognostic indicator in patients with multiple myelomaen
dc.typeJournal articleen
dc.identifier.rmid0020128000en
dc.identifier.doi10.1111/bjh.12280en
dc.identifier.pubid19798-
pubs.library.collectionMedicine publicationsen
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidVandyke, K. [0000-0002-1033-849X]en
dc.identifier.orcidZannettino, A. [0000-0002-6646-6167]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.